Scarica l'app Stockscreener
1.02
0.00%
0.00
Pre-mercato:
1.03
0.01
+0.98%
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
AKBA Technical Analysis & Stock Price Forecast - Intellectia AI
Is the options market predicting a spike in Akebia Therapeutics stock? - MSN
Akebia plunges 20% on muted Q1 print - MSN
Number of shareholders of Akebia Therapeutics, Inc. – NASDAQ:AKBA - TradingView
Earnings call transcript: Akebia Therapeutics Q1 2026 reports EPS miss, stock falls - Investing.com Canada
Korsana deal and cash crunch reshape Cyclerion (NASDAQ: CYCN) outlook - Stock Titan
State Street (AKBA) reports 11.6M-share, 4.3% stake in Akebia - Stock Titan
HC Wainwright Issues Negative Estimate for AKBA Earnings - MarketBeat
TradingKey - TradingKey
Akebia outlines phase II FSGS study of up to ~60 patients as Vafseo reaches nearly 7,500 patients - MSN
Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results - simplywall.st
Analysts Are Updating Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Estimates After Its First-Quarter Results - Yahoo Finance
Akebia Q1 2026 earnings preview - MSN
HC Wainwright Expects Lower Earnings for Akebia Therapeutics - MarketBeat
Akebia Therapeutics (AKBA) Is Down 14.5% After Swing To Q1 Loss And Share Increase Plan - Sahm
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2026 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics (AKBA) Receives a Buy from H.C. Wainwright - The Globe and Mail
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by Wall Street Zen - MarketBeat
Akebia Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Akebia Therapeutics(AKBA) Stock Options Chain | Quotes & News - Moomoo
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Akebia (AKBA) Q1 2026 Earnings Transcript - AOL.com
Akebia Therapeutics, Inc. (NASDAQ:AKBA): Is Breakeven Near? - 富途牛牛
Q1 2026 Akebia Therapeutics Inc Earnings Call Transcript - GuruFocus
AKBA SEC FilingsAkebia Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by Zacks Research - MarketBeat
Akebia Therapeutics, Inc. (AKBA) Investor Outlook: A Biotech with Significant Upside Potential - DirectorsTalk Interviews
Akebia Therapeutics (AKBA) Losses Narrow To US$9.1 Million Challenging Bearish Profitability Narratives - Sahm
Akebia Therapeutics (NASDAQ:AKBA) Posts Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Akebia Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Akebia Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Akebia Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Akebia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Akebia Therapeutics Q1 Earnings Call Highlights - MarketBeat
Earnings call transcript: Akebia’s Q1 2026 results miss forecasts, stock drops - Investing.com Canada
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Akebia Therapeutics (NASDAQ: AKBA) swings to Q1 2026 loss amid new Auryxia generic - Stock Titan
AKBA: Vafseo growth and pipeline advances offset Auryxia declines, with cash to fund operations for two years - TradingView
Akebia Therapeutics: Q1 Earnings Snapshot - KVUE
Akebia (NASDAQ: AKBA) Q1 2026 loss amid Auryxia decline, Vafseo growth - Stock Titan
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights - GlobeNewswire
Key facts: Akebia Q1 $53.5M revenue, $9.1M loss; VOCAL/VOICE timeline - TradingView
MSN Money - MSN
Akebia Therapeutics (AKBA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Akebia Therapeutics Inc expected to post a loss of 3 cents a shareEarnings Preview - TradingView
Akebia gives 7 new hires stock options tied to 208,800 shares - Stock Titan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology - marketscreener.com
1.92%
4.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):